HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

9-(2-hydroxy-3-nonyl)adenine (EHNA)

Subscribe to New Research on 9-(2-hydroxy-3-nonyl)adenine

specific inhibitor of adenosine deaminase; RN given refers to cpd without isomeric designation; structure

Also Known As:

EHNA; 9-(2-hydroxy-3-nonyl)adenine hydrochloride; 9-(2-hydroxy-3-nonyl)adenine monohycrochloride; 9-(2-hydroxy-3-nonyl)adenine monohycrochloride, (erythro-R*,S*)-isomer; 9-(2-hydroxy-3-nonyl)adenine oxalate (2:1); 9-(2-hydroxy-3-nonyl)adenine oxalate (2:1), (erythro-R*,R*)-isomer; 9-(2-hydroxy-3-nonyl)adenine, (R*,S*)-(+-)-isomer; 9-(2-hydroxy-3-nonyl)adenine, (R*,S*)-isomer; 9-(2-hydroxy-3-nonyl)adenine, (R-(R*,R*))-isomer; 9-(2-hydroxy-3-nonyl)adenine, (R-(R*,S*))-isomer; 9-(2-hydroxy-3-nonyl)adenine, (S-(R*,R*))-isomer; 9-(2-hydroxy-3-nonyl)adenine, (S-(R*,S*))-isomer; erythro-9-(2-hydroxy-3-nonyl)adenine; erythro-9-(2-hydroxynon-3-yl)adenine; erythro-9-(3-(2-hydroxynonyl))adenine; threo-9-(2-hydroxy-3-nonyl)adenine; 6-amino beta-hexyl alpha-methyl-9H-purine-9-ethanol

Networked: 67 relevant articles (5 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 60
- 2-Ring Heterocyclic Compounds
  - Purines: 436
    - Adenine: 1702
      - 9-(2-hydroxy-3-nonyl)adenine: 67

Experts

1.	Nakano, Takashi: 2 articles (01/2015 - 04/2010)
2.	Nishizaki, Tomoyuki: 2 articles (01/2015 - 04/2010)
3.	Wechsler, Andrew S: 2 articles (10/2013 - 07/2012)
4.	Jessen, Michael E: 2 articles (10/2013 - 07/2012)
5.	Abd-Elfattah, Anwar Saad: 2 articles (10/2013 - 07/2012)
6.	Colucci, Rocchina: 2 articles (11/2010 - 08/2007)
7.	Antonioli, Luca: 2 articles (11/2010 - 08/2007)
8.	Fornai, Matteo: 2 articles (11/2010 - 08/2007)
9.	Blandizzi, Corrado: 2 articles (11/2010 - 08/2007)
10.	Duranti, Emiliano: 2 articles (11/2010 - 08/2007)

Related Diseases

1.	Ischemia 04/01/1990 - "Results showed that EHNA can inhibit the increase of cardiac resting tension during ischemia period and decreasing the incidence of ventricular fibrillation and its duration. " 07/01/2012 - "Three boluses of the vehicle (series A) or 100 μM EHNA and 25 μM NBMPR (series B) were infused into the pump at baseline, before ischemia and before reperfusion. " 02/01/2001 - "The treatment with iodotubercidin did not alter ischemia-induced increase in adenosine (0.84 +/- 0.18 micromol/l); however, EHNA alone markedly enhanced adenosine accumulation (13.54 +/- 2.16 micromol/l), the value of which was not augmented by an addition of iodotubercidin (15.80 +/- 1.24 micromol/l). " 03/01/1998 - "Each animal received intravenously 30 ml of either a vehicle solution or 100 M EHNA and 25 M NBMPR 10 min before ischemia. " 12/01/1996 - "An injection of EHNA into the eye before ischemia reduced the thinning of the inner plexiform and nuclear retinal layers so that no significant difference between them and the control retinas existed. "
2.	Inflammation 08/01/2007 - "These findings indicate that 1) inhibition of adenosine deaminase results in a significant attenuation of intestinal inflammation and 2) the novel compound APP is more effective than EHNA in reducing systemic and intestinal inflammatory alterations." 11/01/2010 - "APP, EHNA, and dexamethasone counteracted the increments of spleen weight, ameliorated macroscopic and microscopic indexes of inflammation, and reduced TNF-α, IL-6, and MDA levels. " 02/01/2011 - "Our findings show that the inhibition of adenosine deaminase by EHNA can prevent Clostridium difficile TxA-induced damage and inflammation possibly through the A(2A) adenosine receptor, suggesting that the modulation of adenosine/adenosine deaminase represents an important tool in the management of C. "
3.	Heart Arrest (Cardiac Arrest) 07/01/1982 - "EHNA + adenosine in a 0.05 mM Ca++ infusion solution conserved ATP, markedly improved the functional recovery of hearts, and thus may have a role to play in myocardial preservation during elective cardiac arrest."
4.	Body Weight (Weight, Body) 11/01/2010 - "APP or EHNA, but not dexamethasone, improved food intake and body weight. "
5.	Experimental Arthritis 06/01/2007 - "The objectives were: (1) to test the association of methotrexate (MTX) efficacy in rat adjuvant arthritis (rat AA) with interference of purine biosynthesis and adenosine metabolism and (2) to test the efficacy of erythro-9-(2-hydroxynon-3-yl) adenine (EHNA), an inhibitor of adenosine deaminase, and the efficacy of aminoimidazolecarboxamide (AICA) riboside plus MTX in rat AA. "

Related Drugs and Biologics

1.	9-(2-hydroxy-3-nonyl)adenine (EHNA)
2.	Adenosine Deaminase
3.	Adenosine
4.	Adenine
5.	Adenosine Triphosphate (ATP)
6.	Dexamethasone (Maxidex)
7.	Dipyridamole (Persantine)
8.	purine
9.	acadesine
10.	Placebos

Related Therapies and Procedures

1.	Intraperitoneal Injections
2.	Cardiopulmonary Bypass (Heart-Lung Bypass)
3.	Warm Ischemia
4.	Ligation
5.	Induced Heart Arrest (Cardioplegia)